
==== Front
Dig Dis Sci
Dig Dis Sci
Digestive Diseases and Sciences
0163-2116
1573-2568
Springer US New York

39001958
8543
10.1007/s10620-024-08543-1
Original Article
Elemental Diet as a Therapeutic Modality: A Comprehensive Review
Nasser Jason 12
Mehravar Sepideh 1
Pimentel Mark 12
Lim Jane 12
Mathur Ruchi 13
Boustany Antoine 4
Rezaie Ali ali.rezaie@cshs.org

12
1 Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, 700 N. San Vicente Blvd, Suite G271, West Hollywood, CA 90069 USA
2 Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA USA
3 Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles, CA USA
4 grid.239578.2 0000 0001 0675 4725 Department of Medicine, Cleveland Clinic Foundation, Cleveland, OH USA
13 7 2024
13 7 2024
2024
69 9 33443360
29 4 2024
21 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Elemental diets have been employed for the management of various diseases for over 50 years, with several mechanisms mediating their beneficial effects. Yet, they are underutilized due to poor palatability, access, cost, and lack of awareness regarding their clinical efficacy. Therefore, in this review, we aimed to systematically search and review the literature to summarize the formulation variability, mechanisms of action, clinical applications, and tolerability of the elemental diets in gastrointestinal diseases. While large prospective trials are lacking, elemental diets appear to exhibit objective and subjective clinical benefit in several diseases, including eosinophilic esophagitis, eosinophilic gastroenteritis, inflammatory bowel diseases, small intestinal bacterial overgrowth, intestinal methanogen overgrowth, chemoradiotherapy-associated mucositis, and celiac disease. Although some data support the long-term use of elemental diets as an add-on supplement for chronic pancreatitis and Crohn’s disease, most of the literature on exclusive elemental diets focuses on inducing remission. Therefore, subsequent treatment strategies for maintaining remission need to be adopted in chronic/relapsing diseases. Several mechanistic pathways were identified to mediate the effects of elemental diets, including food additive and allergen-free content, high passive absorption rate, and anti-inflammatory properties. High rates of intolerance up to 40% are seen in the trials where exclusive elemental diets were administered orally due to poor organoleptic acceptability; however, when tolerated, adverse events were rare. Other limitations of elemental diets are cost, access, and lifestyle/social restrictions. Moreover, judicious use is advised in presence of a concomitant restrictive food intake disorders. Elemental diets offer a potentially highly efficacious dietary intervention with minor side effects. Palatability, cost, access, and social restrictions are common barriers of use. Prospective clinical trials are needed to elucidate the role of elemental formulas in the management of individual diseases.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10620-024-08543-1.

Keywords

Elemental diet
Enteral nutrition
Crohn’s disease
Small intestinal bacterial overgrowth
Intestinal methanogen overgrowth
Eosinophilic esophagitis
Cedars-Sinai Medical CenterOpen access funding provided by SCELC, Statewide California Electronic Library Consortium

issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcIntroduction

Elemental diets (EDs) have been used for more than 50 years for various conditions and illnesses. Whereas polymeric diets contain whole proteins and oligomeric diets contain short peptides, the nitrogen content of EDs typically consists of free amino acids [1]. The lipid content of EDs consists of medium chain triglycerides, which passively diffuse into the portal system, with or without additional long-chain triglycerides. The carbohydrate content of the elemental diets generally consists of monosaccharides (dextrose, glucose, or maltose) or easily digestible saccharide polymers, such as maltodextrins. EDs are complete nutritional sources and contain the daily requirements of vitamins and minerals.

The production and mixing processes of ED formulas continue to be highly complex and necessitate involvement of specialized food engineering laboratories. EDs are devoid of allergens and can be largely absorbed without active digestion, allowing for rapid absorption and high nutritional efficacy. As such, EDs have favorable characteristics to be effective for several gastrointestinal (GI) and systemic diseases, particularly those driven by atopy, indigestion, and malabsorption. They further possess anti-inflammatory and mucosal healing properties that contribute to their utility in inflammatory conditions. Given their high absorbability index, EDs generate little fecal bulk, which provides additional benefit in severe diarrhea, high output ostomies, and gastrointestinal fistulae. (Fig. 1) Many of these GI diseases have limited therapeutic options, particularly when first-line therapies are unsuccessful, a gap which elemental nutrition therapy may be able to fill as an adjunct or stand-alone therapeutic and nutritional intervention.Fig. 1 Mechanistic pathways through which elemental diets exert their beneficial effects

In addition to its utility in the management of GI diseases, ED has been shown to have potential use in the management of non-GI atopic illnesses such as perennial asthma and inflammatory illnesses such as rheumatoid arthritis [2, 3]. ED can be of particular benefit in the pre-, peri-, and post-operative management of patients undergoing pancreaticoduodenectomy, gastrectomy, ileal resection, or colectomy in the management of malignancy or inflammatory bowel disease [4–7].

The main barriers to the widespread use of EDs include poor palatability, high out-of-pocket cost, and lack of provider awareness. While numerous studies have investigated the application of EDs in various diseases, these valuable insights remain scattered across the literature, posing a challenge in accessing this information. The aim of this review is to provide a comprehensive elucidation of formulation variability, mechanisms of action, clinical applications, and tolerability of elemental diet as a therapeutic modality in GI disorders.

Methods

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews (PRISMA-ScR) [8], we systematically searched three electronic databases: MEDLINE, PubMed, and the Cochrane Database for Systematic Reviews and Cochrane Central Register for Controlled Trials for relevant articles from inception until September 2023. The search strategy was designed to identify all studies evaluating the effect of ED in treating various GI diseases. Study designs included randomized controlled trials (RCTs), systematic reviews, case–control studies, cohort studies, cross-sectional studies, case series, and case reports. The exclusion criteria included studies involving animal subjects, non-English literature, conference abstracts and review articles and editorials. For indications where a systematic review or meta-analysis has already been completed, the results of these reviews were preferentially discussed. Further details regarding the search strategy, eligibility criteria, reviewing process, and study selection flow diagram are described in the supplementary material.

Results

The initial database search yielded a total of 1243 articles. After removing 583 duplicates, 660 records remained for screening. Among these, 51 studies met the inclusion criteria and were included in the review and presented based on disease state (Supplementary Fig. 1).

Eosinophilic Esophagitis (EoE)

EDs have been used in the management of EoE in pediatric patients since the description of the disease, with the first report on efficacy being published in 1995 by Kelly et al. [9]. (Table 1) In this study 10 proton pump inhibitor (PPI)-refractory children with EoE (6 also failed fundoplication) underwent a minimum of 6 weeks of exclusive ED. All subjects showed symptomatic response (80% resolution and 20% improvement of symptoms) along with endoscopic and histologic improvement. Subsequent studies in pediatric cohorts assessing exclusive ED therapy reproduced high rates of response ranging from 75 to 95%. A recent meta-analysis determined the pooled efficacy of ED in EoE to be 91% (95% CI 85%-96%) [10].Table 1 Studies assessing the effect of exclusive elemental diet in eosinophilic esophagitis and eosinophilic gastroenteritis

Author (year)	Country	Study type	Participants	Diet intervention	Elemental diet*	Control group	Route of feeding	Treatment duration	Outcomes of interest	
Gonsalves (2023)[14]	USA	Prospective	15 adults with histologically active EoG/EoGE*	Exclusive elemental diet	Elemental

Neocate Jr, Neocate Splash, or Elecare Jr

	N/A	Oral	6 weeks	100% complete histologic remission in the stomach and duodenum	
Warners (2017)[12]	Netherlands	Prospective	21 adults with histologically active EoE	Exclusive elemental diet	Elemental diet (Neocate Nutricia)	N/A	Oral	4 weeks	71% complete histologic response, 24% partial histologic response (> 50% drop in eos). 19% did not tolerate the diet	
Al-Hussaini (2013)[72]	Saudi Arabia	Prospective	14 children with histologically active EoE (4 patients on elemental diet)	Exclusive elemental diet	Amino acid-based milk formula (Neocate)	Allergy testing guided-dietary restriction (n = 10)	Oral or NG	Minimum of 2 months	Histologic remission in 3 out of 4 (75%) of children receiving elemental diet vs 60% treatment failure and partial remission with dietary restriction	
Peterson (2013)[11]	USA	Prospective	18 adults with histologically active EoE	Exclusive elemental diet	Elemental diet (Elecare Free Amino Acid-based Medical Food)	N/A	Oral	2–4 weeks	Complete/near complete response in 72% of subjects (< 10 eos/HPF) and 22% partial response (> 50% drop in eos). 38% non-adherence to the diet	
Henderson (2012)[73]	USA	Retrospective	98 children with PPI-unresponsive histologically active EoE (49 patients on elemental diet)	Exclusive elemental diet	Neocate or E028 Splash (Nutricia North America, Rockville, Md) or EleCare (Abbott Laboratories, Columbus, Ohio)	6-food elimination (n = 26) and directed diets (n = 23)	Oral (55%) and NG (45%)	4.5 months	Histologic remission occurred in 96%, 81%, and 65% of patients on elemental, 6-food elimination, and directed diets, respectively	
Kagalwalla (2012)[74]	USA	Retrospective	161 children with histologically active EoE (12 patients on elemental diet)	Exclusive elemental diet	Not available	Milk elimination (n = 17), elimination diet (n = 82), topical steroids (n = 37), elimination diet plus steroids (n = 13)	Not available	Not available	Histologic remission in 83%, 65%, 63%, 62%, and 46% for elemental diet, milk elimination, elimination diet, topical steroids, and elimination diet + steroids, respectively	
Liacouras (2005)[75]	USA	Retrospective	172 children with histologically active EoE non-responsive to elimination diet among 392 study participants	Exclusive elemental diet	Neocate, Neocate EO28	N/A	Oral (20%) or NG (80%)	Not available	97% of patients demonstrated clinical and histologic improvement. No weight loss or growth retardation was observed	
Kelly (1995)[76]	USA	Prospective	10 children with histologically active EoE	Non-exclusive elemental diet (clear liquids were allowed)	Elemental formulas

Neocate or Neocate-l-Plus (Scientific Hospital Supplies

Inc., Gaithersburg, MD)

	N/A	Oral (20%), NG (40%), oral & NG (40%)	Minimum of 6 weeks	Patients receiving the formulas had either resolution (80%) or improvement of symptoms (20%). Median eos/hpf count dropped from 41 to 1 after diet	
EOE Eosinophilic esophagitis, EoG/EoGE Eosinophilic gastritis/gastroenteritis, PPI proton pump inhibitor, NG nasogastric tube, eos/HPF eosinophil/ high-power field

Two prospective studies have investigated the efficacy of exclusive ED in adult EoE [11, 12]. Peterson et al. assessed the efficacy of 4 weeks of ED (2 weeks if their response was complete at week 2 endoscopy) on 29 adult patients with EoE. All patients underwent at least 8 weeks of PPI therapy prior to baseline endoscopy. Compliance was poor as 11 subjects (38%) could not tolerate the elemental diet (Elecare). Of the remaining 18 subjects, one had complete response (< 2 eos/hpf) at 2 weeks and the rest completed 4 weeks of ED. Presence of endoscopic furrows and exudates significantly dropped from 78 and 56% to 17% and 6%, respectively (p < 0.01). However, the reduction in the rate of strictures (39% vs 28%) was not statistically significant (p = 0.21). Overall, there was a fivefold decrease in tissue eosinophil count (54 to 10 eos/hpf, p < 0.01). Of 18 subjects, 9 (50%) had complete histologic response (< 5 eos/hpf), 2 (12%) had near complete response (< 6–10 eos/hpf), 4 had partial histologic response (> 10 eos/hpf but > 50% drop in eosinophil count), and 1 (6%) failed (only 18% drop in eosinophil count at 4 weeks). Eight subjects were steroid refractory with 50% complete response similar to non-steroid refractory cases. Mast cell counts also significantly dropped from 32 to 14/hpf (p < 0.01). Six subjects underwent repeat endoscopy after introduction of solid food which showed recurrence of eosinophils but not mast cells.

Warners et al. prospectively assessed 34 adults with EoE. Only 17 subjects were able to finish 4 weeks of ED therapy (50% drop-out rate) mostly due to unpalatability. Of 17 patients, 16 (94%) showed complete (n = 12) or partial histologic response (n = 4). Peak tissue eosinophil count dropped from 40 to 9/hpf, while mast cell counts were unchanged (10 to 7/hpf, p = 0.82). Significant improvement in the number of patients with severe/moderate eczema was observed (76% vs 30%, p = 0.01). Significant endoscopic improvement was observed as the mean endoscopic reference score dropped from 7 to 3 after the diet (p < 0.01). Fifteen patients (88%) became completely asymptomatic [12]. Peripheral eosinophil counts, IgE levels, interleukin (IL)-5, IL-13, and thymic stromal lymphopoietin significantly decreased after diet. Disease recurrence was seen in all six subjects who underwent follow-up endoscopy at 6 months after reintroducing all food groups.

In the clinical guidelines by the American Gastroenterological Association and the Joint Task Force on Allergy-Immunology Practice Parameters, ED was described to have the highest response rate across treatment interventions, receiving a conditional recommendation for use in EoE [13] with moderate quality of evidence. The conditional recommendation cited the difficulty of adherence and high cost as areas of concern. Overall, exclusive elemental diets appear to be highly effective in induction of remission in EOE; however, a strategy needs to be adopted for maintenance of remission following completion of the diet. Further studies are needed to elucidate which maintenance therapy (e.g., food elimination diet, partial ED, topical/systemic immunomodulators, or monoclonal antibodies) is superior in this setting.

Eosinophilic Gastritis/Gastroenteritis (EGID)

Gonsalves et al. assessed the efficacy of ED in 15 cases of eosinophilic gastritis and gastroenteritis in a prospective, single-arm trial. Of 15 subjects, 14 had failed at least one standard of care treatment, including PPIs, steroids, immunosuppressive therapy, or elimination diets. All 15 subjects had complete histologic remission (< 30 eos/hpf) in both the stomach and duodenum after 6 weeks of ED [14]. Average eosinophil count dropped from 50 to 11 eos/hpf in the stomach and from 49 to 16 in the duodenum (p < 0.01). An average weight loss of 5.9% was observed. Furthermore, all patients had improvements in molecular disease activity, endoscopic signs, and symptoms, including pain and fatigue. Thirteen patients who pursued regular food reintroduction experienced disease relapse. Microbiome analysis showed increased abundance of Firmicutes, Porphyromonadaceae, and Veillonellaceae and decreased Bacteroidetes, Ruminococcaceae, and Bacteroidaceae.

Of the 18 patients who initially started the diet, two (10.5%) withdrew due to inability adhere to exclusive diet and one patient was withdrawn after developing hyponatremia in the context of having renal insufficiency, multiple diuretics, and ingesting less than the recommended amount of the formula and an excess of free water.

Similar to EOE, EGID appears to be highly responsive to exclusive ED. To decrease the chance of recurrence after the diet, patients may require to be on a maintenance therapy, such as food elimination diets, partial ED, or immunosuppressive therapy.

Inflammatory Bowel Disease (IBD)

Nutrition and dietary interventions are critical steps in the management of IBD patients with and without undernutrition. Exclusive enteral nutrition (EEN) with intake of liquid elemental, semi-elemental, or polymeric formulas for 6–8 weeks has been shown to be effective in Crohn’s disease (CD). In children and adolescents, EEN is recommended as first-line therapy [15] for induction of remission. ED is of particular interest in patients with active disease as a stand-alone or adjunct to induction therapy.

A 2018 Cochrane systematic review [16] of 11 trials showed that ED has similar rate of induction of remission in CD (63.8%) as compared to non-elemental diet enteral feeds (62.5%, p = 0.83, n = 378) with no difference in adverse events (Relative risk 1.01, 95% CI 0.62–1.65, n = 323).

A 3 to 6 weeks of ED appear to be effective in inducing clinical, endoscopic, and histologic remission in CD. (Table 2) Effect of ED in ulcerative colitis (UC) is only assessed in one small study in 1989 where 24 mild to severe UC patients were randomized to an ED (n = 12) or a blended normal diet (n = 12) for two weeks. Five patients withdrew from the study due to taste, but significant clinical improvement was noticed in both groups. The role of ED in management of UC remains to be elucidated. Of note, the ED used in this trial contained 70–90% short-chain peptide and 10–30% free amino acids which underlines the variability in definition “elemental diet” especially in older studies which needs to be taken into consideration when assessing the efficacy of Eds (Supplementary Table 1). Fat composition of elemental diet is also important as high large-chain triglyceride content has been linked to lower efficacy of ED in CD [17].Table 2 Studies assessing the effect of exclusive elemental diet in inflammatory bowel disease

Author (year)	Country	Participants	Type of study	Diet intervention	Elemental diet*	Control group	Route of feeding	Treatment duration	Outcomes of interest	
Grogan (2012)[77]	UK	34 children with active CD (15 on ED)	Prospective	Exclusive enteral nutrition	Emsogen	Polymeric (n = 19)	NG then oral	6 weeks	Numerically higher remission rates were seen with ED (93%) vs polymeric diet (79%)	
Johnson (2006)[18]	UK	50 children with active CD (24 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028 extra	Partial enteral nutrition (50%) (n = 26)	Oral	6 weeks	Higher rate of remission was seen with exclusive ED (42%) vs partial ED (15%, p = 0.03)0.36% withdrew from the study	
Canani (2005)[78]	Italy	47 children with active CD (12 on ED)	Retrospective	Exclusive enteral nutrition	Elemental	Prednisolone (n = 10)

Semi-elemental (n = 13)

Polymeric (n = 12)

	NG	8 Weeks	ED induced higher clinical, endoscopic and histologic remission as compared to prednisolone	
Ludvigsson (2004) [79]	Sweden	33 children with active CD (16 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028	Polymeric (n = 17)	NG or oral	6 weeks	Remission rates with ED (69%) and polymeric diet (82%, p = 0.4) did not differ	
Sakurai (2002)[80]	Japan	36 adults with active CD (18 on ED)	Prospective	Exclusive enteral nutrition	Elental	Polymeric with high MCT content (n = 18)	Nasoduodenal	6 weeks	ED and polymeric diets induced remission at similar rates (67% vs. 72%)	
Verma (2000)[81]	UK	21 adults with active CD (10 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028	Polymeric(n = 11)	NG	4 weeks	Numerically higher remission rate with ED (80%) vs. polymeric diet (55%, p = 0.1)	
Mansfield (1995)[82]	UK	44 adults with active CD (22 on ED)	Prospective	Exclusive enteral nutrition	E028	Semi-elemental (n = 22)	NG	4 weeks	Similar clinical remission rates were seen between ED (36.4%) and semi-elemental diets (36.4%). Responder showed decreased inflammation of technetium leukocyte scanning	
Middleton (1995) [17]	UK	76 adults with active CD (17 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028	E028 + MCT (n = 19), E028 + LCT (n = 22), semi-elemenal (n = 18)	NG or oral	3 weeks	Remission rates in Peptide 2 +, E028, E028 + MCT, and Eo28 + LCT were 87%, 92%, 92%, and 55%, respectively. Only E028 and E028 + MCT decreases inflammatory markers. 25.7% could not tolerate oral feeding	
Papadopoulou (1995) [83]	UK	36 children with active CD (19 on ED)	Retrospective	Exclusive enteral nutrition	Elemental 028	Oral prednisolone (n = 17)	NG or oral	6 weeks	ED and steroids induced similar clinical remission rates. ED performed better than prednisolone in proximal CD and improvement of nutritional status/growth	
Royall (1994)[84]	Canada	40 hospitalized adults with active CD (19 on ED)	Prospective	Exclusive enteral nutrition	Vivonex TEN	Semi-elemental (n = 21)	Inpatient nasoduodenal	3 weeks	Elemental and semi-elemental diets induced remission at similar rates (84% vs. 75%, p = 0.4). Total body nitrogen increased only with ED	
Gorard (1993)[19]	UK	42 adults with active CD (22 on ED)	Prospective	Exclusive enteral nutrition	Vivonex TEN	Prednisolone (n = 20)	NG or oral	4 Weeks	When tolerated (41% intolerance rate), induction of remission with ED (77%) is as effective as prednisolone (85%) independent of nutritional state	
Thomas (1993)[85]	UK	24 children with active CD (12 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028	Sulfasalazine plus predinosolone (n = 12)	NG or oral	4 weeks	ED and steroids/sulfasalazine induced similar clinical remission rates. ED induced higher growth velocity	
Park (1991) [86]	UK	14 adults with active CD (7 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028	Polymeric (n = 7)	NG	4 weeks	Clinical remission of 29% for elemental diet and 71% with polymeric diet	
Raouf (1991)[87]	UK	24 adults with active CD (13 on ED)	Prospective	Exclusive enteral nutrition	Elemental 028	Polymeric (n = 11)	NG	3 weeks	ED and polymeric diet induced clinical remission at similar rates (69% vs. 73%). Reintroduction for green vegetables were identified as a risk factor for relapse	
Rigaud (1991)[88]	France	30 adults with steroid -refractory active CD (15 on ED)	Prospective	Exclusive enteral nutrition	Vivonex	Polymeric (n = 15)	NG	4–6 weeks	ED and polymeric diets induced similar clinical remission (67% vs. 73%) and endoscopic improvement (40% vs. 40%)	
Giaffer (1990)[89]	UK	30 adults with active CD (16 on ED)	Prospective	Exclusive enteral nutrition	Vivonex	Polymeric diet (Fortison) (n = 14)	NG	4 weeks	Higher clinical remission in ED (75%) vs polymeric diet (36%, p < 0.03)	
Okada (1990)[90]	Japan	20 adults with active CD (10 on ED)	Prospective	Exclusive enteral nutrition	Elental	Prednisolone (n = 10)	Nasoduodenal	4 weeks	Clinical and inflammatory marker remission of 80% with elemental diet vs 11% with steroids	
Munkholm larsen (1989)[91]	Denmark	24 adults with active UC (12 on elemental diet) and 19 CD (9 on ED)	Prospective	Exclusive enteral nutrition	Pepti 2000	Blended normal diet (CD n = 10)

(UC n = 12)

	Oral	2 weeks	Both diets improved clinical remission in UC but not CD. 28% dropped out due to taste	
Sanderson (1987) [92]	UK	17 children with active small bowel CD (9 on ED)	Prospective	Exclusive enteral nutrition	Flexical	Sulfasalazine plus prednisolones (n = 8)	NG	6 weeks	ED and steroids/sulfasalazine induced similar clinical remission rates reduction of inflammatory markers. ED induced higher growth velocity	
C O'Moráin (1984) [93]	UK	21 adults with active CD (11 on ED)	Prospective	Exclusive enteral nutrition	Vivonex	Prednisolone (n = 10)	Oral inpatient	4 weeks	ED and steroids induced similar clinical remission rates (81% vs 80%) at 4 weeks	
McLaughlin SD (2013) [94]	UK	7 adults with active pouchitis (UC)	Prospective	Exclusive enteral nutrition	Elemental 028	Not applicable	Oral	4 weeks	Significant improvement in clinical PDAI score in 5 out of 7ubjects	
CD Crohn disease, UC ulcerative colitis, ED elemental diet, MCT Medium-chain triglycerides, LCT Long-chain triglyceride

*Definition of elemental diet was variable in the studies. Some formulations contain up to 90% short-chain peptides and up to 50% long-chain triglycerides (please refer to supplementary Table 1 for detailed diet composition)

Notably, owing to known poor oral tolerance and palatability, in the majority of the studies exclusive ED was delivered via tube feeding (Table 2). Where ED was given orally, rates of intolerance in pediatric [18] and adult [19] patients are reported up to 36% and 41%, respectively.

While several studies [20–22] have assessed the addition of elemental diet to regular food, the efficacy of exclusive ED for maintenance of remission in IBD is not yet evaluated.

Overall, ED appears to be highly effective in inducing remission in adult and pediatric CD. Upon induction of remission, an appropriate maintenance of remission strategy should be adopted.

Small Intestinal Bacterial Overgrowth/Intestinal Methanogen Overgrowth

While antibiotics are the mainstay of treatment for small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO), their overall efficacy is limited at 50% or less [23, 24]. Elemental diet provides an alternative option to treat patients who are refractory, cannot tolerate antibiotics, or prefer a non-antibiotic treatment approach. [20]Pimentel et al. conducted a retrospective study on patients with irritable bowel syndrome (IBS) and hydrogen-predominant SIBO (based on abnormal lactulose hydrogen breath testing). Subjects took 14 days of ED (Vivonex Plus, Nestle) and if breath test remained abnormal, they were encouraged to take the diet for an additional 7 days. Of 124 included subjects, 93 had complete records or could tolerate the diet for analysis. Normalization of breath test was observed in 80% after 14 days and another 5% normalized with an extension to 21 days. Significant clinical improvement in symptoms (66%) was noticed among 28 patients who normalized their breath and had clinical data available [25]. Rezaie et al. evaluated an oral palatable ED (Mbiota Elemental) in a prospective clinical trial on 30 subjects with IMO and/or SIBO. All patients were able to tolerate 14 days of exclusive ED and a significant drop in maximum methane levels (41 ± 35 to 12 ± 15 ppm, p < 0.001) and peak hydrogen rise (43 ± 42 to 12 ± 11 ppm, p < 0.001) were observed. Complete normalization of breath test was seen in 100%, 58%, and 75% in SIBO (n = 6), IMO (n = 12), and IMO/SIBO (n = 12), respectively. No serious or severe adverse effects were observed [26].

Overall, ED appears to be effective in treatment of IMO or SIBO. However, studies with longer period of follow-up are needed to assess the response durability and the role of maintenance strategies.

Celiac Disease and Dermatitis Herpetiformis

We identified three studies describing the efficacy of the ED in dermatitis herpetiformis and celiac disease, 1 in celiac disease, and 3 in refractory celiac disease. Kadunce et al. conducted a trial on 8 adult patients with dermatitis herpetiformis on dapsone, 6 of whom were given an exclusive ED (Vivonex TEN) plus 30 g of gluten for 2 weeks followed by the ED alone for 2 weeks, while 2 subjects were given the dietary intervention in reverse order [27]. Subjects started regular diet one month prior to the trial. Dapsone was discontinued three days before the study start date. All patients underwent fluoroscopic small bowel biopsies at days 0, 14, and 28. Following the 2-week ED plus gluten phase, 100% of patients (7/7) demonstrated histologic worsening of their celiac disease and after only 2 weeks on the exclusive ED period, 100% (6/6) demonstrated histologic improvement. Interestingly, 6 out of 8 subjects experienced improvement of their rash during the ED with gluten exposure phase, with all 8 experiencing improvement by the end of the study [27]. Two older studies published in 1981 and 1986 described mixed results in the intestinal histologic response of 7 patients with celiac disease and dermatitis herpetiformis after a trial of elemental diet despite significant improvement in their skin lesions, although these studies were limited by having used Crosby-Kugler capsules to obtain the small bowel biopsies [28, 29]. As opposed to endoscopy, this technique utilizes an orally ingested tube to obtain small bowel biopsies without direct visualization [30].

In a study on presumable celiac disease diagnosed by Crosby-Kugler capsule and clinical symptoms, 4 weeks of exclusive elemental diet (n = 4, Vivonex) achieved similar clinical improvement as gluten-free diet (n = 4). Modest histologic improvement was noticed in both groups [31].

The three studies describing the role of ED in refractory celiac included a prospective study of ED (E028) for four weeks on 10 patients with Type 1 refractory celiac disease despite strict gluten-free diet. One patient dropped out and 6/9 patients demonstrated clinical improvement, while 8/9 demonstrated histologic improvement and decreased IL-15 [32]. Otherwise, 2 case reports were identified, one with symptomatic and histologic improvement of a middle-aged woman on the ED with the patient electing to extend the ED to 10 weeks, later returning to a GFD and remaining asymptomatic [33]. The other described a patient with steroid refractory CD who showed no significant clinical or histologic response to 6 weeks of ED, necessitating a change in treatment and eventually responding to infliximab [34].

Overall, limited data suggest a potential role for ED in treatment of refractory celiac disease type 1 and dermatitis herpetiformis; however, the role of ED in non-refractory Celiac disease requires further evaluation.

Acute Pancreatitis

A limited number of studies were found describing the use of ED in acute pancreatitis. Endo et al. conducted a retrospective cohort study using a national database, identifying patients with acute pancreatitis who received enteral tube feeding within 3 days of admission [35]. There was no significant difference observed for in-hospital mortality, hospital-free days, total health-care costs, and sepsis development between those who received an elemental diet (Elental, n = 382) and those who received non-elemental enteral nutrition (n = 566) [35]. On the other hand, Voitk et al. assessed six patients with complicated severe acute pancreatitis unable to tolerate regular diet and unsuitable for parenteral nutrition. Five of the 6 patients experienced clinical improvement, weight gain, and eventual recovery, while one patient initially improved but later succumbed to a hemorrhagic complication of severe pancreatitis [36].

Overall, current data do not show a clear advantage of ED over other enteral feeding formulas in the treatment of patients with acute pancreatitis. Prospective controlled trials are needed the effect of ED in acute pancreatitis.

Chronic Pancreatitis

Two studies have described the benefit of supplementing with 300–1200 kCal of ED in chronic pancreatitis. A prospective cohort including 596 patients with chronic pancreatitis and chronic pain found clinical improvement in response to partial ED supplementation with a decrease in abdominal pain from 52.9 to 20.0 mm on the visual analog scale after 12 weeks (p < 0.001), with an associated improvement in nutritional indices [37]. Another prospective cohort included 17 chronic pancreatitis patients with chronic pain, finding that partial ED supplementation resulted in complete pain resolution in 59% of patients and pain improvement in 29% [38].

Overall, supplemental ED appears promising in improving pain in patients with chronic pancreatitis. Larger studies are needed to assess the magnitude and durability of response.

Intestinal Lymphangiectasia

Intestinal lymphangiectasia is an acquired or congenital disease complicated with protein losing enteropathy at varying severity [39]. While total parenteral therapy, steroids, and MCT oils have been used for treatment of intestinal lymphangiectasia, one retrospective study and one case report have assessed the role of ED. Aoyagi et al. retrospectively assessed four patients on ED (Elental) for 4–6 weeks and response (increased serum total protein) was seen 3/4 patients. Both patients with objective enteric protein loss normalized [39]. In 2001, Kuroiwa et al. described a patient with octreotide-responsive intestinal lymphangiectasia who did not experience clinical or laboratory improvement with ED, although the duration of the ED trial was not reported [40].

Very limited data exist on the role ED in treatment of intestinal lymphangiectasia. Further prospective trails are needed.

Bile Acid Diarrhea

Two studies investigated the role of the ED in bile acid diarrhea. In 1977, Nelson et al. assessed six patients with bile acid diarrhea secondary to ileal resection who received ED for 8–15 days, and they showed a reduction in their fecal bile acid excretion with marked improvement in their diarrhea and reduction in stool frequency, volume, and urgency [41]. In 1979, Russell et al. reported three patients with non-surgical, Crohn’s-related ileal malabsorption and bile acid diarrhea with marked reduction of fecal bile acid output, and improvement in their stool frequency and consistency during 2–3 weeks of treatment with ED [42]. Of note, neither of these studies ruled out SIBO as a common cause of bile acid malabsorption which is also responsive to ED [43].

Larger prospective trials with up-to-date diagnostic evaluations are needed to assess the role of EDs in bile acid diarrhea.

Risk of Aspiration Associated with Percutaneous Endoscopic Gastrostomy (PEG)

Two publications examined the role of ED in preventing aspiration, both by Horiuchi et al., in 2013 and 2019. In the 2013 publication, consecutive bedridden PEG patients received either ED (n = 60) or standard liquid diets (n = 67). None of those receiving the ED experienced aspiration or aspiration pneumonia, while those receiving the standard liquid diet developed aspiration in 11.9% (p < 0.01) and aspiration pneumonia in 7.5% (p = 0.03) [44]. In their subsequent study, 19 patients were randomized to ED or standard liquid diets with subsequent crossover. Rates of gastric emptying were significantly faster with the ED compared to the standard liquid diet [44]. In 2019, a similar study recruiting 18 consecutive bedridden PEG patients who received the ED, showed one episode (5.6%) of aspiration from the trachea and no episodes of aspiration pneumonia [45].

Overall, ED shows promise in decreasing aspiration events in patients with PEG. Larger studies are needed to assess the magnitude and durability of response.

Prevention of Chemoradiation-Induced Oral Mucositis

Approximately 20–40% of patients with solid tumors undergoing chemotherapy develop mucositis [46]. No trials investigating an exclusive ED were identified, although numerous trials investigated the role of partial ED. A systematic review and meta-analysis by Tanaka et al. in 2022 included 9 studies (6 RCTs and 3 observational studies) and found that partial ED supplementation significantly reduces oral mucositis (grade 2–4) associated with chemotherapy/radiotherapy (OR 0.25, 95 CI 0.10–0.61) [46].

Overall, current data supports supplemental ED in prevention of chemoradiation-induced oral mucositis.

Other Published Uses Outside the Scope of this Review

Multiple other uses for the elemental diet were evident in our search, although they were outside the scope of our review. These included reducing GI bleeding in burn victims [47], severe asthma, severe eczema, Cronkhite–Canada syndrome, orofacial granulomatosis, rheumatoid arthritis, chylothorax, and chylous ascites [2, 3, 48–50]. There are also several publications regarding the utility of ED in the perioperative setting for multiple surgeries, including gastrectomy, colectomy, short bowel syndrome, and pancreaticoduodenectomy [5, 6, 51]. No studies were identified to be investigating the benefit of ED in adult food allergies, metabolic syndrome, lactose intolerance, sucrose intolerance, or non-celiac gluten intolerance.

Discussion

EDs have broad applications as stand-alone or adjunct therapy across several GI diseases, many of which have otherwise limited treatment options. The mechanisms by which EDs benefit patients are multifold and vary depending on the underlying disease pathogenesis:Allergen-free content: As the protein content of an ED is completely hydrolyzed, it is intrinsically allergen free. This imparts a distinct benefit in the treatment of allergen-driven diseases, including EoE and EGID, celiac disease, and food allergies. Lack of food allergens minimizes the mucosal immune response with potential benefit in IBD.

Bypass of digestion: EDs require minimal to no digestion and as such are readily absorbable in the proximal small intestine. This allows it to bypass exocrine pancreatic insufficiency, biliary pathology, and enzymatic deficiencies, such as lactase and sucrase/isomaltase deficiency.

Decreased GI exocrine stimulation: The hydrolyzed protein and minimal fat content modulate the luminal stimulation of gastrointestinal hormones and pancreatobiliary secretions. There is evidence [52] that the ED is a weaker stimulus of pancreatic secretions compared to a regular diet, potentially contributing to its alleviation of pain associated with chronic pancreatitis.

Optimal nutritional value: ED is a complete diet that provides all necessary macronutrients and micronutrients with an adjustable daily caloric target which effectively addresses undernutrition, malnutrition, and their associated morbidities.

Low-fat content: While high-fat diets are proinflammatory, ED is a low-fat diet, further contributing to its anti-inflammatory effect [53]. Furthermore, MCTs possess several beneficial effects, including anti-inflammatory properties [54].

Low fecal bulk: The minimal non-absorbable content and high absorption rate of EDs are associated with a decrease in fecal stream which may benefit certain diseases, such as CD and fistulae [55]. Interestingly, total parenteral therapy has not been associated with remission of IBD, emphasizing that low fecal bulk is not a critical pathway for benefits seen with ED [56].

Modulation of the gut microbiome: ED has been shown to be an effective treatment for small intestinal bacterial overgrowth, likely as a result of the extensive proximal absorption of nutrients with minimal residual luminal nutrients in the distal small bowel and colon, directly inhibiting bacterial growth. The diet further [14, 57] influences the composition of the gut flora which itself has been suggested to contribute to the beneficial effects of the diet.

Free amino acid content: The free amino acid content of EDs play an important role in mediating their beneficial impact. Glutamine is essential for the growth of rapidly dividing cells, such as epithelial cells. Glutamine supplementation in isolation has been shown to heal and prevent mucosal damage in disease states with impaired mucosal turnover, such as in patients receiving chemotherapy and radiotherapy [58]. It has been shown to improve tight junction protein expression [59] and intestinal permeability in various disease states, including IBS [60], severe burns [61], and IBD [62]. It is also the precursor of glutathione [63], which is a major endogenous antioxidant that protects against apoptosis and cellular stresses. Histidine possesses antioxidant and anti-inflammatory properties [64] that have the potential to positively impact gastrointestinal tract health. While there are no human studies investigating histidine, a rodent model of colitis showed [65] that histidine inhibited NF-κB activation and downregulated downstream proinflammatory cytokine production. Similar to glutamine, arginine stimulates cellular pathways [66] that enhance mucosal cell proliferation, cytoprotection, and recovery. Arginine plays a particularly important role as a precursor for nitric oxide, a vasodilator, and key regulator of intestinal motility through relaxing intestinal smooth muscle cells. Finally, proline, threonine, and serine [67] are critical to the intestinal mucosal barrier as they form mucin glycoproteins.

Food additive-free content: True EDs are devoid of food additives including emulsifiers, artificial sweeteners, food colorants, and nanoparticles which have been implicated in pathogenesis of various diseases, including IBD and IBS [68].

While ED can provide 100% of daily nutrition requirements [69], it should be noted that conventional formulas to calculate daily basal metabolic rate likely overestimate the required daily calories during exclusive ED consumption. Active digestion accounts for 10% of daily energy expenditure which significantly reduces with exclusive ED. In addition, unlike non-elemental diets, EDs are optimally absorbed and a higher digestibility coefficient leads to higher calorie harvest [70].

Our findings show that the main limiting factor in implementing an ED is patient intolerance due to taste with study withdrawal rates up to 41%. In pediatric population, this has generally been mitigated by enteral tube feeding, a strategy which is not typically feasible in adult and adolescent subjects especially in outpatient settings. Hence, development of organoleptically acceptable elemental formulations is key to increase the compliance and tolerance rates of patients. Similarly, this can pave the way to use elemental diets for maintenance of remission of relevant GI disorders rather than induction of remission phase. Barriers of cost and access are also notable, particularly as nutritional therapies are often not covered by insurance providers with high out-of-pocket costs. Patient advocacy efforts to increase patient access and insurance coverage are critical.

Avoidant/restrictive food intake disorders with aversion to certain foods based on their sensory characteristics, or a fear of the consequences of eating, or a lack of interest in eating can be seen pediatric and even adult patients suffering from chronic diseases. In the presence of such disorders, caution should be exerted in initiation of strict or restrictive diets or dietary formulations. A multidisciplinary approach remains the ideal approach to care for these patients [71].

Our study has several limitations. Typically, blinding is a challenge in diet trials which can affect the estimation of therapeutic effect. Definition of EDs in terms of fat, carbohydrate and even small peptide content had variability among the studies. The interpretation of the results of included studies should take into account the constitution of each elemental diet (Supplementary Table).

In conclusion, despite cost and palatability barriers, elemental diet offers a potentially highly efficacious intervention with minor side effects in various inflammatory and non-inflammatory GI disorders. Future studies should focus on ameliorating barriers of use and improving the optimal micro- and macronutrient content of elemental diets.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 62 KB)

Author’s contributions

Conceptualization: AR, JN, and MP; Formal analysis: AR, SM, JN, and AB; Funding acquisition: AR and MP; Investigation: AR and JN; Methodology: AR, JN, and AB; Project administration: AR, MP, and RM; Supervision: AR; Visualization: JN and SM; Writing – original draft: JN, AR, SM, and JL; Writing – review & editing: JL, JN, MP, RM, AR, and SM.

Funding

Open access funding provided by SCELC, Statewide California Electronic Library Consortium. Funding in part were provided by the John and Geraldine Cusenza Family Foundation.

Declarations

Competing interests

MP is a consultant for Ferring Pharmaceuticals, Inc, Salvo Health, Dieta Health, and Vivante Health, Inc has received grant support from Bausch Health, and has equity in Gemelli Biotech, Dieta Health, Salvo Health, Vivante Health, and Good LFE. RM has equity in Gemelli Biotech and Good LFE. AR is a consultant/speaker for Bausch Health and has equity in Gemelli Biotech and Good LFE. Cedars-Sinai has licensing agreements with Hobbs Medical and Gemelli Biotech. All other authors report no conflicts of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jason Nasser and Sepideh Mehravar are contributed equally to this work.
==== Refs
References

1. Koretz RL Meyer JH Elemental diets–facts and fantasies Gastroenterology. 1980 78 393 410 10.1016/0016-5085(80)90594-6 6985599
Koretz RL, Meyer JH. Elemental diets–facts and fantasies. Gastroenterology. 1980Feb;78:393–410.6985599
2. Høj L Osterballe O Bundgaard A Weeke B Weiss M A double-blind controlled trial of elemental diet in severe, perennial asthma Allergy. 1981 36 257 262 10.1111/j.1398-9995.1981.tb01572.x 7032340
Høj L, Osterballe O, Bundgaard A, Weeke B, Weiss M. A double-blind controlled trial of elemental diet in severe, perennial asthma. Allergy. 1981May;36:257–262.7032340
3. Podas T Nightingale JM Oldham R Roy S Sheehan NJ Mayberry JF Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone Postgrad Med J. 2007 83 128 131 10.1136/pgmj.2006.050245 17308218
Podas T, Nightingale JM, Oldham R, Roy S, Sheehan NJ, Mayberry JF. Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone. Postgrad Med J. 2007Feb;83:128–131.17308218
4. Imamura H Nishikawa K Kishi K Inoue K Matsuyama J Akamaru Y Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial Ann Surg Oncol. 2016 23 2928 2935 10.1245/s10434-016-5221-4 27084538
Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y et al. Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial. Ann Surg Oncol. 2016Sep;23:2928–2935.27084538
5. Shichinohe T Sasaki T Kitashiro S Morita T Ono K Senmaru N Impact of elemental diet on early recovery after laparoscopic colectomy: findings of a randomized controlled trial Surg Today. 2017 47 166 173 10.1007/s00595-016-1365-x 27324516
Shichinohe T, Sasaki T, Kitashiro S, Morita T, Ono K, Senmaru N et al. Impact of elemental diet on early recovery after laparoscopic colectomy: findings of a randomized controlled trial. Surg Today. 2017Feb;47:166–173.27324516
6. Mori R Matsuyama R Taniguchi K Goto K Miyake K Hiratani S Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A pilot prospective randomized trial IN000004108) Clin Nutr ESPEN. 2019 34 116 124 10.1016/j.clnesp.2019.07.017 31677701
Mori R, Matsuyama R, Taniguchi K, Goto K, Miyake K, Hiratani S et al. Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A pilot prospective randomized trial IN000004108). Clin Nutr ESPEN. 2019Dec;34:116–124.31677701
7. Yamamoto T Nakahigashi M Shimoyama T Umegae S Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn's disease? A case-matched study. Colorectal Dis. 2020 22 554 561 10.1111/codi.14922 31782874
Yamamoto T, Nakahigashi M, Shimoyama T, Umegae S. Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn’s disease? A case-matched study. Colorectal Dis. 2020May;22:554–561.31782874
8. Tricco AC Lillie E Zarin W O'Brien KK Colquhoun H Levac D PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation Ann Intern Med. 2018 2 467 473 10.7326/M18-0850
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018Oct;2:467–473.
9. Van Dellen RG Lewis JC Oral administration of cromolyn in a patient with protein-losing enteropathy, food allergy, and eosinophilic gastroenteritis Mayo Clin Proc. 1994 69 441 444 10.1016/S0025-6196(12)61640-1 8170195
Van Dellen RG, Lewis JC. Oral administration of cromolyn in a patient with protein-losing enteropathy, food allergy, and eosinophilic gastroenteritis. Mayo Clin Proc. 1994May;69:441–444.8170195
10. Arias A González-Cervera J Tenias JM Lucendo AJ Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis Gastroenterology. 2014 146 1639 1648 10.1053/j.gastro.2014.02.006 24534634
Arias A, González-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014Jun;146:1639–1648.24534634
11. Peterson KA Byrne KR Vinson LA Ying J Boynton KK Fang JC Elemental diet induces histologic response in adult eosinophilic esophagitis Am J Gastroenterol. 2013 108 759 766 10.1038/ajg.2012.468 23381017
Peterson KA, Byrne KR, Vinson LA, Ying J, Boynton KK, Fang JC et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol. 2013May;108:759–766.23381017
12. Warners MJ Vlieg-Boerstra BJ Verheij J van Rhijn BD Van Ampting MT Harthoorn LF Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients Aliment Pharmacol Ther. 2017 45 777 787 10.1111/apt.13953 28112427
Warners MJ, Vlieg-Boerstra BJ, Verheij J, van Rhijn BD, Van Ampting MT, Harthoorn LF et al. Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients. Aliment Pharmacol Ther. 2017Mar;45:777–787.28112427
13. Hirano I Chan ES Rank MA Sharaf RN Stollman NH Stukus DR AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis Gastroenterology. 2020 158 1776 1786 10.1053/j.gastro.2020.02.038 32359562
Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020May;158:1776–1786.32359562
14. Gonsalves N Doerfler B Zalewski A Yang GY Martin LJ Zhang X Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial J Allergy Clin Immunol. 2023 152 676 688 10.1016/j.jaci.2023.05.024 37462600
Gonsalves N, Doerfler B, Zalewski A, Yang GY, Martin LJ, Zhang X et al. Prospective study of an amino acid-based elemental diet in an eosinophilic gastritis and gastroenteritis nutrition trial. J Allergy Clin Immunol. 2023Sep;152:676–688.37462600
15. van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis. 2020 Oct 7.
16. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. 2018 .
17. Middleton SJ Rucker JT Kirby GA Riordan AM Hunter JO Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease Clin Nutr. 1995 14 229 236 10.1016/S0261-5614(95)80004-2 16843936
Middleton SJ, Rucker JT, Kirby GA, Riordan AM, Hunter JO. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn’s disease. Clin Nutr. 1995Aug;14:229–236.16843936
18. Johnson T Macdonald S Hill SM Thomas A Murphy MS Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial Gut. 2006 55 356 361 10.1136/gut.2004.062554 16162683
Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut. 2006Mar;55:356–361.16162683
19. Gorard DA Hunt JB Payne-James JJ Palmer KR Rees RG Clark ML Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone Gut. 1993 34 1198 1202 10.1136/gut.34.9.1198 8406153
Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML et al. Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut. 1993Sep;34:1198–1202.8406153
20. Verma S Holdsworth CD Giaffer MH Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand J Gastroenterol. 2001 36 383 388 10.1080/003655201300051199 11336163
Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand J Gastroenterol. 2001Apr;36:383–388.11336163
21. Takagi S Utsunomiya K Kuriyama S Yokoyama H Takahashi S Iwabuchi M Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial Aliment Pharmacol Ther. 2006 1 1333 1340 10.1111/j.1365-2036.2006.03120.x
Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M et al. Effectiveness of an “half elemental diet” as maintenance therapy for Crohn’s disease: A randomized-controlled trial. Aliment Pharmacol Ther. 2006Nov;1:1333–1340.
22. Hanai H Iida T Takeuchi K Arai H Arai O Abe J Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease Dig Liver Dis. 2012 44 649 654 10.1016/j.dld.2012.03.007 22542605
Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J et al. Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn’s disease. Dig Liver Dis. 2012Aug;44:649–654.22542605
23. Lim J Rezaie A Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes Dig Dis Sci. 2023 68 4081 4097 10.1007/s10620-023-08095-w 37695549
Lim J, Rezaie A. Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes. Dig Dis Sci. 2023Nov;68:4081–4097. 10.1007/s10620-023-08095-w37695549
24. Takakura W Rezaie A Chey WD Wang J Pimentel M Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis J Neurogastroenterol Motil. 2024 30 7 16 10.5056/jnm22187 38173154
Takakura W, Rezaie A, Chey WD, Wang J, Pimentel M. Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil. 2024Jan;30:7–16.38173154
25. Pimentel M Constantino T Kong Y Bajwa M Rezaei A Park S A 14-day elemental diet is highly effective in normalizing the lactulose breath test Dig Dis Sci. 2004 49 73 77 10.1023/B:DDAS.0000011605.43979.e1 14992438
Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004Jan;49:73–77. 10.1023/b:ddas.0000011605.43979.e114992438
26. Rezaie A, Chang BW, Houser K, Mathur R, Brimberry D, Rashid M, Et Al. Mo1359 Compliance, Safety, and Effect of Exclusive Palatable Elemental Diet in Microbial Overgrowth: A Prospective Clinical Trial. Gastroenterology. 2024;166:S-1039.
27. Kadunce DP McMurry MP Avots-Avotins A Chandler JP Meyer LJ Zone JJ The effect of an elemental diet with and without gluten on disease activity in dermatitis herpetiformis J Invest Dermatol. 1991 97 175 182 10.1111/1523-1747.ep12479517 2071933
Kadunce DP, McMurry MP, Avots-Avotins A, Chandler JP, Meyer LJ, Zone JJ. The effect of an elemental diet with and without gluten on disease activity in dermatitis herpetiformis. J Invest Dermatol. 1991Aug;97:175–182.2071933
28. van der Meer JB Zeedijk N Poen H van der Putte SC Rapid improvement of dermatitis herpetiformis after elemental diet Arch Dermatol Res. 1981 271 455 459 10.1007/BF00406693 7332354
van der Meer JB, Zeedijk N, Poen H, van der Putte SC. Rapid improvement of dermatitis herpetiformis after elemental diet. Arch Dermatol Res. 1981;271:455–459.7332354
29. Zeedijk N van der Meer JB Poen H van der Putte SC Dermatitis herpetiformis: consequences of elemental diet Acta Derm Venereol. 1986 66 316 320 10.2340/0001555566316320 2430402
Zeedijk N, van der Meer JB, Poen H, van der Putte SC. Dermatitis herpetiformis: consequences of elemental diet. Acta Derm Venereol. 1986;66:316–320.2430402
30. Greene HL, Rosensweig NS, Lufkin EG, Hagler L, Gozansky D, Taunton OD, et al. Biopsy of the small intestine with the Crosby-Kugler capsule. Experience in 3,866 peroral biopsies in children and adults. Am J Dig Dis. 1974 Mar;19:189–98. 10.1007/BF01072534
31. Russell RI Atherton ST Nelson LM Robertson E Lee FD Effect of an elemental diet vonex) on the absorption abnormalities and histological appearances of the jejunum in untreated adult coeliac disease Digestion. 1979 19 335 339 10.1159/000198383 488554
Russell RI, Atherton ST, Nelson LM, Robertson E, Lee FD. Effect of an elemental diet vonex) on the absorption abnormalities and histological appearances of the jejunum in untreated adult coeliac disease. Digestion. 1979;19:335–339.488554
32. Olaussen RW Løvik A Tollefsen S Andresen PA Vatn MH De Lange T Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease Clin Gastroenterol Hepatol. 2005 3 875 885 10.1016/S1542-3565(05)00295-8 16234025
Olaussen RW, Løvik A, Tollefsen S, Andresen PA, Vatn MH, De Lange T et al. Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease. Clin Gastroenterol Hepatol. 2005Sep;3:875–885.16234025
33. Mandal A Mayberry J Elemental diet in the treatment of refractory coeliac disease Eur J Gastroenterol Hepatol. 2001 13 79 80 10.1097/00042737-200101000-00016 11204817
Mandal A, Mayberry J. Elemental diet in the treatment of refractory coeliac disease. Eur J Gastroenterol Hepatol. 2001Jan;13:79–80.11204817
34. Gillett HR Arnott ID McIntyre M Campbell S Dahele A Priest M Successful infliximab treatment for steroid-refractory celiac disease: a case report Gastroenterology. 2002 122 800 805 10.1053/gast.2002.31874 11875014
Gillett HR, Arnott ID, McIntyre M, Campbell S, Dahele A, Priest M et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology. 2002Mar;122:800–805.11875014
35. Endo A, Shiraishi A, Fushimi K, Murata K, Otomo Y. Comparative effectiveness of elemental formula in the early enteral nutrition management of acute pancreatitis: a retrospective cohort study. Annals of Intensive Care. 2018 2018/06/05;8:69.
36. Voitk A Brown RA Echave V McArdle AH Gurd FN Thompson AG Use of an elemental diet in the treatment of complicated pancreatitis Am J Surg. 1973 125 223 227 10.1016/0002-9610(73)90031-7 4688003
Voitk A, Brown RA, Echave V, McArdle AH, Gurd FN, Thompson AG. Use of an elemental diet in the treatment of complicated pancreatitis. Am J Surg. 1973Feb;125:223–227.4688003
37. Kataoka K Sakagami J Hirota M Masamune A Shimosegawa T Effects of oral ingestion of the elemental diet in patients with painful chronic pancreatitis in the real-life setting in Japan Pancreas. 2014 43 451 457 10.1097/MPA.0000000000000038 24622078
Kataoka K, Sakagami J, Hirota M, Masamune A, Shimosegawa T. Effects of oral ingestion of the elemental diet in patients with painful chronic pancreatitis in the real-life setting in Japan. Pancreas. 2014Apr;43:451–457.24622078
38. Ikeura T Takaoka M Uchida K Miyoshi H Okazaki K Beneficial Effect of Low-Fat Elemental Diet Therapy on Pain in Chronic Pancreatitis Int J Chronic Dis. 2014 2014 862091 26464866
Ikeura T, Takaoka M, Uchida K, Miyoshi H, Okazaki K. Beneficial Effect of Low-Fat Elemental Diet Therapy on Pain in Chronic Pancreatitis. Int J Chronic Dis. 2014;2014:862091.26464866
39. Aoyagi K Iida M Matsumoto T Sakisaka S Enteral nutrition as a primary therapy for intestinal lymphangiectasia: value of elemental diet and polymeric diet compared with total parenteral nutrition Dig Dis Sci. 2005 50 1467 1470 10.1007/s10620-005-2863-7 16110837
Aoyagi K, Iida M, Matsumoto T, Sakisaka S. Enteral nutrition as a primary therapy for intestinal lymphangiectasia: value of elemental diet and polymeric diet compared with total parenteral nutrition. Dig Dis Sci. 2005Aug;50:1467–1470. 10.1007/s10620-005-2863-716110837
40. Kuroiwa G Takayama T Sato Y Takahashi Y Fujita T Nobuoka A Primary intestinal lymphangiectasia successfully treated with octreotide J Gastroenterol. 2001 36 129 132 10.1007/s005350170142 11227670
Kuroiwa G, Takayama T, Sato Y, Takahashi Y, Fujita T, Nobuoka A et al. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol. 2001Feb;36:129–132.11227670
41. Nelson LM Carmichael HA Russell RI Atherton ST Use of an elemental diet (Vivonex) in the management of bile acid-induced diarrhoea Gut. 1977 18 792 794 10.1136/gut.18.10.792 590836
Nelson LM, Carmichael HA, Russell RI, Atherton ST. Use of an elemental diet (Vivonex) in the management of bile acid-induced diarrhoea. Gut. 1977;18:792–794.590836
42. Russell RI Hall MJ Elemental diet therapy in the management of complicated Crohn's disease Scott Med J. 1979 24 291 295 10.1177/003693307902400407 555815
Russell RI, Hall MJ. Elemental diet therapy in the management of complicated Crohn’s disease. Scott Med J. 1979Oct;24:291–295.555815
43. Min YW Rezaie A Pimentel M Bile Acid and Gut Microbiota in Irritable Bowel Syndrome J Neurogastroenterol Motil. 2022 30 549 561 10.5056/jnm22129
Min YW, Rezaie A, Pimentel M. Bile Acid and Gut Microbiota in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2022Oct;30:549–561.
44. Horiuchi A Nakayama Y Sakai R Suzuki M Kajiyama M Tanaka N Elemental diets may reduce the risk of aspiration pneumonia in bedridden gastrostomy-fed patients Am J Gastroenterol. 2013 108 804 810 10.1038/ajg.2013.10 23399554
Horiuchi A, Nakayama Y, Sakai R, Suzuki M, Kajiyama M, Tanaka N. Elemental diets may reduce the risk of aspiration pneumonia in bedridden gastrostomy-fed patients. Am J Gastroenterol. 2013May;108:804–810.23399554
45. Horiuchi A, Sakai R, Tamaki M, Kajiyama M, Tanaka N, Morikawa A. Gastric Emptying of Elemental Liquid Diets Versus Semisolid Diets in Bedridden Gastrostomy-fed Patients. J Clin Gastroenterol. 2019 May/Jun;53:373–78.
46. Tanaka Y Shimokawa T Harada K Yoshida K Effectiveness of elemental diets to prevent oral mucositis associated with cancer therapy: A meta-analysis Clin Nutr ESPEN. 2022 49 172 180 10.1016/j.clnesp.2022.03.005 35623809
Tanaka Y, Shimokawa T, Harada K, Yoshida K. Effectiveness of elemental diets to prevent oral mucositis associated with cancer therapy: A meta-analysis. Clin Nutr ESPEN. 2022Jun;49:172–180.35623809
47. Choctaw WT Fujita C Zawacki BE Prevention of upper gastrointestinal bleeding in burn patients: a role for 'elemental' diet Arch Surg. 1980 115 1073 1076 10.1001/archsurg.1980.01380090047011 6774697
Choctaw WT, Fujita C, Zawacki BE. Prevention of upper gastrointestinal bleeding in burn patients: a role for “elemental” diet. Arch Surg. 1980Sep;115:1073–1076.6774697
48. Hill DJ Lynch BC Elemental diet in the management of severe eczema in childhood Clin Allergy. 1982 12 313 315 10.1111/j.1365-2222.1982.tb02533.x 7105395
Hill DJ, Lynch BC. Elemental diet in the management of severe eczema in childhood. Clin Allergy. 1982May;12:313–315.7105395
49. Sweatman MC, Tasker R, Warner JO, Ferguson MM, Mitchell DN. Oro-facial granulomatosis. Response to elemental diet and provocation by food additives. Clin Allergy. 1986 Jul;16:331–8.
50. Matsumura M Mise Y Takemura N Ono Y Sato T Ito H An Elemental Diet Reduces Chylous Ascites of Patients Undergoing Pancreatoduodenectomy in the Setting of Early Enteral Feeding Pancreas. 2024 1 e343 e349
Matsumura M, Mise Y, Takemura N, Ono Y, Sato T, Ito H et al. An Elemental Diet Reduces Chylous Ascites of Patients Undergoing Pancreatoduodenectomy in the Setting of Early Enteral Feeding. Pancreas. 2024Apr;1:e343–e349.
51. Kimura Y Nishikawa K Kishi K Inoue K Matsuyama J Akamaru Y Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002) Ann Gastroenterol Surg. 2019 3 648 656 10.1002/ags3.12290 31788653
Kimura Y, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y et al. Long-term effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients (KSES002). Ann Gastroenterol Surg. 2019Nov;3:648–656.31788653
52. Keith RG Effect of a low fat elemental diet on pancreatic secretion during pancreatitis Surg Gynecol Obstet. 1980 151 337 343 7404299
Keith RG. Effect of a low fat elemental diet on pancreatic secretion during pancreatitis. Surg Gynecol Obstet. 1980Sep;151:337–343.7404299
53. Bamba T Shimoyama T Sasaki M Tsujikawa T Fukuda Y Koganei K Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial Eur J Gastroenterol Hepatol. 2003 15 151 157 10.1097/00042737-200302000-00008 12560759
Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn’s disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003Feb;15:151–157.12560759
54. Gaete PV, Nieves-Barreto LD, Guatibonza-García V, Losada-Barragán M, Vargas-Sánchez K, Mendivil CO. Medium-chain fatty acids modify macrophage expression of metabolic and inflammatory genes in a PPAR β/δ-dependent manner. Scientific Reports. 2023 2023/07/18;13:11573.
55. Janowitz HD Croen EC Sachar DB The Role of the Fecal Stream in Crohn's Disease: An Historical and Analytic Review Inflammatory Bowel Diseases. 1998 4 29 39 10.1097/00054725-199802000-00006 9552226
Janowitz HD, Croen EC, Sachar DB. The Role of the Fecal Stream in Crohn’s Disease: An Historical and Analytic Review. Inflammatory Bowel Diseases. 1998;4:29–39.9552226
56. Triantafillidis JK Papalois AE The role of total parenteral nutrition in inflammatory bowel disease: current aspects Scand J Gastroenterol. 2014 49 3 14 10.3109/00365521.2013.860557 24354966
Triantafillidis JK, Papalois AE. The role of total parenteral nutrition in inflammatory bowel disease: current aspects. Scand J Gastroenterol. 2014Jan;49:3–14.24354966
57. Deitch EA, Xu D, Qi L, Berg R. Elemental diet-induced immune suppression is caused by both bacterial and dietary factors. JPEN J Parenter Enteral Nutr. 1993 Jul-Aug;17:332–6.
58. Anderson PM Lalla RV Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy Nutrients. 2020 4 12
Anderson PM, Lalla RV. Glutamine for Amelioration of Radiation and Chemotherapy Associated Mucositis during Cancer Therapy. Nutrients. 2020Jun;4:12.
59. Rao R Samak G Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions J Epithel Biol Pharmacol. 2012 5 47 54 10.2174/1875044301205010047 25810794
Rao R, Samak G. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. J Epithel Biol Pharmacol. 2012Jan;5:47–54.25810794
60. Zhou Q Verne ML Fields JZ Lefante JJ Basra S Salameh H Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome Gut. 2019 68 996 1002 10.1136/gutjnl-2017-315136 30108163
Zhou Q, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019Jun;68:996–1002.30108163
61. Peng X Yan H You Z Wang P Wang S Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients Burns. 2004 30 135 139 10.1016/j.burns.2003.09.032 15019120
Peng X, Yan H, You Z, Wang P, Wang S. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. Burns. 2004Mar;30:135–139.15019120
62. Benjamin J Makharia G Ahuja V Anand Rajan KD Kalaivani M Gupta SD Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn's disease: a randomized controlled trial Dig Dis Sci. 2012 57 1000 1012 10.1007/s10620-011-1947-9 22038507
Benjamin J, Makharia G, Ahuja V, Anand Rajan KD, Kalaivani M, Gupta SD et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s disease: a randomized controlled trial. Dig Dis Sci. 2012Apr;57:1000–1012. 10.1007/s10620-011-1947-922038507
63. Tapiero H Mathé G Couvreur P Tew KD II. Glutamine and glutamate Biomed Pharmacother. 2002 56 446 457 10.1016/S0753-3322(02)00285-8 12481981
Tapiero H, Mathé G, Couvreur P, Tew KD. II. Glutamine and glutamate. Biomed Pharmacother. 2002Nov;56:446–457.12481981
64. Wade AM, Tucker HN. Antioxidant characteristics of L-histidine 11The work described in this manuscript was partially sponsored and funded by Cytos Pharmaceuticals, LLC. The Journal of Nutritional Biochemistry. 1998 1998/06/01/;9:308–15.
65. Andou A Hisamatsu T Okamoto S Chinen H Kamada N Kobayashi T Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages Gastroenterology. 2009 136 564 74.e2 10.1053/j.gastro.2008.09.062 19027739
Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology. 2009Feb;136:564–74.e2.19027739
66. Marc Rhoads J, Wu G. Glutamine, arginine, and leucine signaling in the intestine. Amino Acids. 2009 2009/05/01;37:111–22.
67. Johansson MEV, Hansson GC. Immunological aspects of intestinal mucus and mucins. Nature Reviews Immunology. 2016 2016/10/01;16:639–49.
68. Whelan K, Bancil AS, Lindsay JO, Chassaing B. Ultra-processed foods and food additives in gut health and disease. Nature Reviews Gastroenterology & Hepatology. 2024 2024/02/22.
69. Manski S, Noverati N, Policarpo T, Rubin E, Shivashankar R. Diet and Nutrition in Inflammatory Bowel Disease: A Review of the Literature. Crohn's & Colitis 360. 2023;6.
70. Mansilla WD Marinangeli CPF Cargo-Froom C Franczyk A House JD Elango R Comparison of methodologies used to define the protein quality of human foods and support regulatory claims Appl Physiol Nutr Metab. 2020 45 917 926 10.1139/apnm-2019-0757 32706267
Mansilla WD, Marinangeli CPF, Cargo-Froom C, Franczyk A, House JD, Elango R et al. Comparison of methodologies used to define the protein quality of human foods and support regulatory claims. Appl Physiol Nutr Metab. 2020Sep;45:917–926.32706267
71. Treasure J Duarte TA Schmidt U Eating disorders Lancet. 2020 14 899 911 10.1016/S0140-6736(20)30059-3
Treasure J, Duarte TA, Schmidt U. Eating disorders. Lancet. 2020Mar;14:899–911.
72. Al-Hussaini A Al-Idressi E Al-Zahrani M The role of allergy evaluation in children with eosinophilic esophagitis J Gastroenterol. 2013 48 1205 1212 10.1007/s00535-012-0741-6 23354622
Al-Hussaini A, Al-Idressi E, Al-Zahrani M. The role of allergy evaluation in children with eosinophilic esophagitis. J Gastroenterol. 2013Nov;48:1205–1212.23354622
73. Henderson CJ Abonia JP King EC Putnam PE Collins MH Franciosi JP Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis J Allergy Clin Immunol. 2012 129 1570 1578 10.1016/j.jaci.2012.03.023 22541246
Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012Jun;129:1570–1578.22541246
74. Kagalwalla AF Akhtar N Woodruff SA Rea BA Masterson JC Mukkada V Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment J Allergy Clin Immunol. 2012 129 1387 96.e7 10.1016/j.jaci.2012.03.005 22465212
Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol. 2012May;129:1387–96.e7.22465212
75. Liacouras CA Spergel JM Ruchelli E Verma R Mascarenhas M Semeao E Eosinophilic esophagitis: a 10-year experience in 381 children Clin Gastroenterol Hepatol. 2005 3 1198 1206 10.1016/S1542-3565(05)00885-2 16361045
Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol. 2005Dec;3:1198–1206.16361045
76. Kelly KJ Lazenby AJ Rowe PC Yardley JH Perman JA Sampson HA Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula Gastroenterology. 1995 109 1503 1512 10.1016/0016-5085(95)90637-1 7557132
Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995Nov;109:1503–1512.7557132
77. Grogan JL Casson DH Terry A Burdge GC El-Matary W Dalzell AM Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up Inflamm Bowel Dis. 2012 18 246 253 10.1002/ibd.21690 21425210
Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012Feb;18:246–253.21425210
78. Berni Canani R Terrin G Borrelli O Romano MT Manguso F Coruzzo A Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease Dig Liver Dis. 2006 38 381 387 10.1016/j.dld.2005.10.005 16301010
Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis. 2006Jun;38:381–387.16301010
79. Ludvigsson JF Krantz M Bodin L Stenhammar L Lindquist B Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial Acta Paediatr. 2004 93 327 335 10.1111/j.1651-2227.2004.tb02956.x 15124834
Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn’s disease: a multicentre randomized controlled trial. Acta Paediatr. 2004Mar;93:327–335.15124834
80. Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. JPEN J Parenter Enteral Nutr. 2002 Mar-Apr;26:98–103.
81. Verma S Brown S Kirkwood B Giaffer MH Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial Am J Gastroenterol. 2000 95 735 739 10.1111/j.1572-0241.2000.01527.x 10710067
Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am J Gastroenterol. 2000Mar;95:735–739.10710067
82. Mansfield JC Giaffer MH Holdsworth CD Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease Gut. 1995 36 60 66 10.1136/gut.36.1.60 7890238
Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn’s disease. Gut. 1995Jan;36:60–66.7890238
83. Papadopoulou A Rawashdeh MO Brown GA McNeish AS Booth IW Remission following an elemental diet or prednisolone in Crohn's disease Acta Paediatr. 1995 84 79 83 10.1111/j.1651-2227.1995.tb13490.x 7734907
Papadopoulou A, Rawashdeh MO, Brown GA, McNeish AS, Booth IW. Remission following an elemental diet or prednisolone in Crohn’s disease. Acta Paediatr. 1995Jan;84:79–83.7734907
84. Royall D Jeejeebhoy KN Baker JP Allard JP Habal FM Cunnane SC Comparison of amino acid v peptide based enteral diets in active Crohn's disease: clinical and nutritional outcome Gut. 1994 35 783 787 10.1136/gut.35.6.783 8020806
Royall D, Jeejeebhoy KN, Baker JP, Allard JP, Habal FM, Cunnane SC et al. Comparison of amino acid v peptide based enteral diets in active Crohn’s disease: clinical and nutritional outcome. Gut. 1994Jun;35:783–787.8020806
85. Thomas AG Taylor F Miller V Dietary intake and nutritional treatment in childhood Crohn's disease J Pediatr Gastroenterol Nutr. 1993 17 75 81 8350215
Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn’s disease. J Pediatr Gastroenterol Nutr. 1993Jul;17:75–81.8350215
86. Park RHR, Galloway A, Danesh BJZ, Russell RI. Double-blind controlled trial of elemental and polymeric diets as primary therapy in active Crohn's diseas. 1991 01/01;3:483–90.
87. Raouf AH Hildrey V Daniel J Walker RJ Krasner N Elias E Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge Gut. 1991 32 702 707 10.1136/gut.32.6.702 1905672
Raouf AH, Hildrey V, Daniel J, Walker RJ, Krasner N, Elias E et al. Enteral feeding as sole treatment for Crohn’s disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge. Gut. 1991Jun;32:702–707.1905672
88. Rigaud D Cosnes J Le Quintrec Y René E Gendre JP Mignon M Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet Gut. 1991 32 1492 1497 10.1136/gut.32.12.1492 1773955
Rigaud D, Cosnes J, Le Quintrec Y, René E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn’s disease: elemental versus polymeric diet. Gut. 1991Dec;32:1492–1497.1773955
89. Giaffer MH North G Holdsworth CD Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease Lancet. 1990 7 816 819 10.1016/0140-6736(90)90936-Y
Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn’s disease. Lancet. 1990Apr;7:816–819.
90. Okada M Yao T Yamamoto T Takenaka K Imamura K Maeda K Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn's disease Hepatogastroenterology. 1990 37 72 80 2179093
Okada M, Yao T, Yamamoto T, Takenaka K, Imamura K, Maeda K et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterology. 1990Feb;37:72–80.2179093
91. Munkholm Larsen P Rasmussen D Rønn B Munck O Elmgreen J Binder V Elemental diet: a therapeutic approach in chronic inflammatory bowel disease J Intern Med. 1989 225 325 331 10.1111/j.1365-2796.1989.tb00089.x 2659720
Munkholm Larsen P, Rasmussen D, Rønn B, Munck O, Elmgreen J, Binder V. Elemental diet: a therapeutic approach in chronic inflammatory bowel disease. J Intern Med. 1989May;225:325–331.2659720
92. Sanderson IR Udeen S Davies PS Savage MO Walker-Smith JA Remission induced by an elemental diet in small bowel Crohn's disease Arch Dis Child. 1987 62 123 127 10.1136/adc.62.2.123 3548602
Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn’s disease. Arch Dis Child. 1987Feb;62:123–127.3548602
93. O'Morain C Segal AW Levi AJ Elemental diets in treatment of acute Crohn's disease Br Med J. 1980 1 1173 1175 10.1136/bmj.281.6249.1173
O’Morain C, Segal AW, Levi AJ. Elemental diets in treatment of acute Crohn’s disease. Br Med J. 1980Nov;1:1173–1175.
94. McLaughlin SD Culkin A Cole J Clark SK Tekkis PP Ciclitira PJ Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis J Crohns Colitis. 2013 7 460 466 10.1016/j.crohns.2012.07.009 22857825
McLaughlin SD, Culkin A, Cole J, Clark SK, Tekkis PP, Ciclitira PJ et al. Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis. J Crohns Colitis. 2013Jul;7:460–466.22857825
